Table 3.
Five-year relative survival rates (percent) for marginal zone lymphoma (MZL) according to major MZL subtypes and selected extranodal MZL sites, overall and by race/ethnicity, United States, SEER 18, 2000–2017*
| MZL subtype | All | Non-Hispanic Whites | Non-Hispanic Blacks | Non-Hispanic Asian or Pacific Islanders | Hispanics (All Races) |
|---|---|---|---|---|---|
| All MZL | 89.8% | 89.7% | 89.6% | 89.4% | 88.7% |
| Splenic MZL | 85.3% | 85.7% | 83.8% | 84.7% | 76.3% |
| Nodal MZL | 82.8% | 82.7% | 85.3% | 81.0% | 80.5% |
| Extranodal MZL | 93.8% | 94.0% | 91.8% | 91.8% | 93.3% |
| Oral Cavity/Oropharynx | 93.6% | 94.9% | ─ | ─ | ─ |
| Salivary Glands | 97.6% | 97.5% | 96.5% | 99.2% | 96.3% |
| Nasopharynx | 88.5% | 86.6% | ─ | ─ | ─ |
| Stomach | 92.0% | 92.5% | 90.7% | 90.6% | 90.2% |
| Small Intestine | 87.9% | 90.7% | ─ | ─ | ─ |
| Colorectal | 92.5% | 94.1% | 82.6% | 87.3% | 92.2% |
| Lung | 90.9% | 92.4% | 84.3% | 83.2% | 88.1% |
| Skin | 100.0% | 100.0% | 96.0% | 99.1% | 98.9% |
| Soft Tissue | 96.3% | 92.5% | ─ | ─ | ─ |
| Breast (female) | 94.8% | 94.2% | 96.1% | ─ | ─ |
| Kidney and Bladder | 88.4% | 90.3% | ─ | ─ | ─ |
| Eye/Adnexa | 97.9% | 96.7% | 97.0% | 95.6% | 98.3% |
| Thyroid | 98.5% | 98.0% | ─ | ─ | ─ |
*
According to InterLymph Classification as implemented in SEER*Stat, excluding American Indians/Alaska Natives (<50 cases)
─
not reported (<50 cases)